A Phase 2 interventional study of PRO 140 and Historical data in HIV and Human Immunodeficiency Virus, sponsored by CytoDyn, Inc.. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-04-14.
Sponsored by CytoDyn, Inc. · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This study is a Phase 2b study designed to evaluate the efficacy, safety, and tolerability of PRO 140 monotherapy for the maintenance of viral suppression in subjects who are stable on combination antiretroviral therapy.
Consenting subjects will be shifted from their combination antiretroviral regimen to PRO 140 monotherapy for 12 weeks. Total treatment duration with PRO 140 will be 14 weeks with the one week overlap of existing retroviral regimen and PRO 140 at the beginning of the study treatment, and one week overlap at the end of the treatment in subjects who do not experience virologic failure.
This study is a Phase 2b, multi-center study designed to evaluate the efficacy, safety, and tolerability of PRO 140 monotherapy for the maintenance of viral suppression in patients who are stable on combination antiretroviral therapy.
Patient enrollment will be staggered in this study to facilitate adequate safety monitoring. A lead cohort will include 12 subjects. Enrollment of additional 28 subjects will not be initiated until it is approved by the independent Data Monitoring Committee (DMC).
Consenting patients will be shifted from combination antiretroviral regimen to PRO 140 monotherapy for 12 weeks. Total treatment duration with PRO 140 will be up to 14 weeks with the one week overlap of existing retroviral regimen and PRO 140 at the beginning of the study treatment and also one week overlap at the end of the treatment in subjects who do not experience Virologic Failure.
PRO 140 will be administered as a 350 mg subcutaneous injection weekly for up to 14 weeks. Study participants will be monitored for viral rebound on a weekly basis following initiation of PRO 140 monotherapy and will re-initiate their previous antiretroviral regimen if plasma HIV-1 RNA levels rise above 400 copies/ml on two consecutive blood draws at least 3 days apart.
The study will have three phases: Screening Phase, Treatment Phase and Follow-up Phase.
The primary objective is to assess efficacy of PRO 140 monotherapy for the maintenance of viral suppression following substitution of antiretroviral therapy in patients who are stable on combination antiretroviral therapy.
The secondary objective of the trial is to assess the clinical safety and tolerability parameters following substitution of antiretroviral therapy in patients who are stable on combination antiretroviral therapy.
3,038 studies on the registry are indexed under Acquired Immunodeficiency Syndrome; 308 are open to participants now.
This study's enrollment of 43 is below the median of 96 across 2,253 interventional studies indexed under Acquired Immunodeficiency Syndrome.
Browse Acquired Immunodeficiency Syndrome studies →CytoDyn, Inc. is the lead sponsor of 24 studies on the registry; none are open to participants now.
Of its 12 completed or terminated interventional studies of FDA-regulated products, 12 (100%) have results posted.
Compared within Acquired Immunodeficiency Syndrome, the registry's first condition term, which may not be this study's main condition. Counted across the registry records on this site, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CD4 count
The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
PRO 140 350mg weekly SQ injection.
Drug: PRO 140 · Other: Historical data
CCR5 Antagonist
Also known as: PRO 140 350mg
Historical data (i.e., time to HIV-1 RNA viral load \> 500 copies/mL of 29 days).
Time to Virologic Failure After Initiating PRO 140 Monotherapy.
Time to virologic failure after initiating PRO 140 monotherapy. Virologic failure was defined as two (2) consecutive HIV-1 RNA levels of ≥ 400 copies/mL.
Time frame: From initiation of PRO 140 monotherapy through week 14 or virological failure
Proportion of Subjects With Virologic Failure
Proportion of Participants with Virologic Failure after initiating PRO 140 monotherapy at or prior to Week 14.
Time frame: From initiation of PRO 140 monotherapy through week 14
Mean Change From Baseline in Viral Load
Mean change in Viral Load (HIV-1 RNA levels - log 10 copies/ml)), at each visit within the 14-week treatment phase.
Time frame: From initiation of PRO 140 monotherapy through week 14
Change in Viral Load at the Last Virologic Failure Visit.
Mean Change from Baseline in viral load at the last virologic failure visit from Week 1 to Week 14. VF can occur at any time during the treatment phase from week 1 to week 14. Subjects who experience Virologic Failure will be followed up every 4 weeks until the viral load suppression is achieved (i.e., plasma HIV-1 RNA levels to return back to \<50 copies/mL)
Time frame: From baseline to virologic failure visit (VF). VF can occur at any time from Week 1 to Week 14.
Mean Change in CD4 Cell Count by Visit
Mean change in CD4 cell count, at each visit within the 14-week treatment phase
Time frame: From baseline (week 2) through week 14
Mean Change in CD4 Cell Count
Change from baseline in CD4 cell count, within the 14-week treatment phase
Time frame: From baseline (week 2) to last visit
Q1 QOL Health Status
Quality of Life Q1 Current General Health Status, is collected from base line to virologic failure (VF can occur at any time from any time during the treatment phase from week 1 to week 14). Subjects who experience Virologic Failure will be followed up every 4 weeks until the viral load suppression is achieved (i.e., plasma HIV-1 RNA levels to return back to \<50 copies/mL)
Time frame: From baseline to virologic failure (VF occurring at any time from Week 1 to Week 12 or virologic failure which ever comes first)
Q2 QOL Current State of Health
Subjects will rate their current state of health via Visual Analog Scale (VAS) using the line as a guide, with 0 as death or worst possible health and 100 as perfect or best possible health. A higher score indicates best outcome. Subjects may experience Virologic Failure (VF) any time during the treatment phase from week 1 to week 14. Subjects who experience VF will be followed up every 4 weeks until the viral load suppression is achieved (i.e., plasma HIV-1 RNA levels to return back to \<50 copies/mL)
Time frame: From week 1 through treatment weeks 4, 8, 12 or VF visit
Injection Site Reaction - Pain (Site 1)
Injection site reaction pain assessment @ injection site 1. Each subject received half the total dose of the IP into two separate injection sites. (injection site 1 and injection site 2) at each treatment visit. The information is reported under separate outcomes measures for each injection site.
Time frame: From initiation of PRO 140 monotherapy through week 14
Injection Site Reaction - Pain (Site 2)
Injection site reaction pain assessment @ injection site 2. Each subject received half the total dose of the IP into two separate injection sites. (injection site 1 and injection site 2) at each treatment visit. The information is reported under separate outcomes measures for each injection site.
Time frame: From initiation of PRO 140 monotherapy through week 14
Injection Site Reaction - Injection Site Status (Site 1)
Summary of injection site reaction assessment - Injection site status @ injection site 1. Each subject received half the total dose of the IP into two separate injection sites. (injection site 1 and injection site 2) at each treatment visit. The information is reported under separate outcomes measures for each injection site.
Time frame: From initiation of PRO 140 monotherapy through week 14
Injection SIte Reaction - Injection Site Status (Site 2)
Summary of injection site reaction assessment - Injection site status @ injection site 2. Each subject received half the total dose of the IP into two separate injection sites. (injection site 1 and injection site 2) at each treatment visit. The information is reported under separate outcomes measures for each injection site.
Time frame: From initiation of PRO 140 monotherapy through week 14
Injection Site Reaction - Pruritus With Injection (Site 1)
Summary of injection site reaction assessment - Pruritus with injection @Site 1. Each subject received half the total dose of the IP into two separate injection sites. (injection site 1 and injection site 2) at each treatment visit. The information is reported under separate outcomes measures for each injection site.
Time frame: From initiation of PRO 140 monotherapy through week 14
Injection Site Reaction - Pruritus With Injection (Site 2)
Summary of injection site reaction assessment - Pruritus with injection @ Site 2. Each subject received half the total dose of the IP into two separate injection sites. (injection site 1 and injection site 2) at each treatment visit. The information is reported under separate outcomes measures for each injection site.
Time frame: From initiation of PRO 140 monotherapy through week14
Injection Site Reaction - Bleeding Site 1
Summary of injection site reaction assessment - bleeding @ Site 1. Each subject received half the total dose of the IP into two separate injection sites. (injection site 1 and injection site 2) at each treatment visit. The information is reported under separate outcomes measures for each injection site.
Time frame: From initiation of PRO 140 monotherapy through week 14
Injection Site Reaction - Bleeding - Site 2
Summary of injection site reaction assessment - bleeding @ Site 2. Each subject received half the total dose of the IP into two separate injection sites. (injection site 1 and injection site 2) at each treatment visit. The information is reported under separate outcomes measures for each injection site.
Time frame: From initiation of PRO 140 monotherapy through week14
Injection Site Reaction - Drug Absorption - Site 1
Summary of injection site reaction assessment - drug absorption @ Site 1. Each subject received half the total dose of the IP into two separate injection sites. (injection site 1 and injection site 2) at each treatment visit. The information is reported under separate outcomes measures for each injection site.
Time frame: From initiation of PRO 140 monotherapy through week14
Injection Site Reaction - Drug Absorption - Site 2
Summary of injection site reaction assessment - drug absorption @ Site 2. Each subject received half the total dose of the IP into two separate injection sites. (injection site 1 and injection site 2) at each treatment visit. The information is reported under separate outcomes measures for each injection site.
Time frame: From initiation of PRO 140 monotherapy through week 14
Injection Site Reaction - Pain Post Injection - Site 1
Summary of injection site pain assessment (VAS) post injection mean change from baseline. Subject-perceived injection site pain was assessed using the Pain Visual Analog Scale (VAS) post study treatment administration assessing average pain. Higher score is worse outcome. Each subject received half the total dose of the IP into two separate injection sites. (injection site 1 and injection site 2) at each treatment visit. The information is reported under separate outcomes measures for each injection site.
Time frame: From initiation of PRO 140 monotherapy through week 14
Injection Site Reaction - Pain Post Injection - Site 2
Summary of injection site pain assessment (VAS) post injection @ Site 2. Subject-perceived injection site pain was assessed using the Pain Visual Analog Scale (VAS) post study treatment administration assessing average pain. A higher score is a worse outcome. Each subject received half the total dose of the IP into two separate injection sites. (injection site 1 and injection site 2) at each treatment visit. The information is reported under separate outcomes measures for each injection site.
Time frame: From initiation of PRO 140 monotherapy through week 14
Injection Site Reaction - Pain Pre Injection - Site 1
Summary of injection site pain assessment (VAS) pre injection @ Site 1 Subject-perceived injection site pain was assessed using the Pain Visual Analog Scale (VAS) prior to study treatment administration assessing average pain since last treatment. Higher score is a worse outcome. Each subject received half the total dose of the IP into two separate injection sites. (injection site 1 and injection site 2) at each treatment visit. The information is reported under separate outcomes measures for each injection site.
Time frame: From week 2 through week 14
Injection Site Reaction - Pain Pre Injection - Site 2
Summary of injection site pain assessment (VAS) pre injection @ Site 2. Subject-perceived injection site pain was assessed using the Pain Visual Analog Scale (VAS) prior to study treatment administration assessing average pain since last treatment. Higher score is a worse outcome. Each subject received half the total dose of the IP into two separate injection sites. (injection site 1 and injection site 2) at each treatment visit. The information is reported under separate outcomes measures for each injection site.
Time frame: From week 2 through week 14
Pro 140 Concentration
Summary of Pro 140 Concentration. Subjects may experience Virologic Failure (VF) any time during the treatment phase from week 1 to week 14. Subjects who experience VF will be followed up every 4 weeks until the viral load suppression is achieved (i.e., plasma HIV-1 RNA levels to return back to \<50 copies/mL).
Time frame: At week 4, week 8, week 12 and viral failure visits
| Milestone | PRO 140 350 mg Weekly SQ Injection |
|---|---|
| Started | 43 |
| Completed | 41 |
| Not completed | 2 |
| Withdrew: Non-compliance | 1 |
| Withdrew: Other non-medical reason | 1 |
Time to virologic failure after initiating PRO 140 monotherapy. Virologic failure was defined as two (2) consecutive HIV-1 RNA levels of ≥ 400 copies/mL.
| days | PRO 140 350 mg |
|---|---|
| Time to Virologic Failure After Initiating PRO 140 Monotherapy. | 70.71 ± 23.14 |
Proportion of Participants with Virologic Failure after initiating PRO 140 monotherapy at or prior to Week 14.
| poportion of subjects | PRO 140 350 mg |
|---|---|
| Proportion of Subjects With Virologic Failure | 0.439 |
Mean change in Viral Load (HIV-1 RNA levels - log 10 copies/ml)), at each visit within the 14-week treatment phase.
| log 10 copies/mL | PRO 140 |
|---|---|
| T2 (Week 2) | 0.10 ± 0.71 |
| T3 (Week 3) | 0.01 ± 0.74 |
| T4 (Week 4) | -0.13 ± 0.74 |
| T5 (Week 5) | -0.25 ± 1.04 |
| T6 (Week 6) | -0.76 ± 1.39 |
| T7 (Week 7) | -0.88 ± 1.53 |
| T8 (Week 8) | -0.72 ± 1.37 |
| T9 (Week 9) | -0.84 ± 1.37 |
| T10 (Week 10) | -0.71 ± 1.36 |
| T11 (Week 11) | -0.81 ± 1.37 |
| T12 (Week 12) | -0.91 ± 1.50 |
| T13 (Week 13) | -0.44 ± 1.12 |
| T14 (Week 14) | -0.37 ± 1.09 |
Mean Change from Baseline in viral load at the last virologic failure visit from Week 1 to Week 14. VF can occur at any time during the treatment phase from week 1 to week 14. Subjects who experience Virologic Failure will be followed up every 4 weeks until the viral load suppression is achieved (i.e., plasma HIV-1 RNA levels to return back to \<50 copies/mL)
| log 10 copies/ml | PRO 140 350 mg Weekly SQ Injection |
|---|---|
| Change in Viral Load at the Last Virologic Failure Visit. | -1.78 ± 1.93 |
Mean change in CD4 cell count, at each visit within the 14-week treatment phase
| cells/mm^3 | PRO 140 |
|---|---|
| T2 (Week 2) | 32.05 ± 132.92 |
| T3 (Week 3) | -33.14 ± 137.05 |
| T4 (Week 4) | -12.78 ± 137.37 |
| T5 (Week 5) | 33.42 ± 130.88 |
| T6 (Week 6) | -3.26 ± 125.78 |
| T7 (Week 7) | 47.50 ± 190.10 |
| T8 (Week 8) | -55.09 ± 157.21 |
| T9 (Week 9) | 47.25 ± 95.64 |
| T10 (Week 10) | -6.82 ± 140.34 |
| T11 (Week 11) | -29.83 ± 218.64 |
| T12 (Week 12) | 16.52 ± 143.91 |
| T13 (Week 13) | -0.44 ± 95.54 |
| T14 (Week 14) | -59.03 ± 56.50 |
| VF (Viral failure) | 18.41 ± 113.99 |
Change from baseline in CD4 cell count, within the 14-week treatment phase
| cells/mm^3 | PRO 140 |
|---|---|
| Mean Change in CD4 Cell Count | 18.97 ± 114.08 |
Quality of Life Q1 Current General Health Status, is collected from base line to virologic failure (VF can occur at any time from any time during the treatment phase from week 1 to week 14). Subjects who experience Virologic Failure will be followed up every 4 weeks until the viral load suppression is achieved (i.e., plasma HIV-1 RNA levels to return back to \<50 copies/mL)
| Participants | PRO 140 350 mg |
|---|---|
| T1 (Week 1) — Poor | 0 |
| T1 (Week 1) — Fair | 1 |
| T1 (Week 1) — Good | 6 |
| T1 (Week 1) — Very Good | 10 |
| T1 (Week 1) — Excellent | 13 |
| T1 (Week 1) — Missing | 11 |
| T4 (Week 4) — Poor | 0 |
| T4 (Week 4) — Fair | 1 |
| T4 (Week 4) — Good | 6 |
| T4 (Week 4) — Very Good | 11 |
| T4 (Week 4) — Excellent | 12 |
| T4 (Week 4) — Missing | 11 |
| T8 (Week 8) — Poor | 1 |
| T8 (Week 8) — Fair | 2 |
| T8 (Week 8) — Good | 6 |
| T8 (Week 8) — Very Good | 9 |
| T8 (Week 8) — Excellent | 9 |
| T8 (Week 8) — Missing | 14 |
| T12 (Week 12) — Poor | 0 |
| T12 (Week 12) — Fair | 2 |
| T12 (Week 12) — Good | 2 |
| T12 (Week 12) — Very Good | 12 |
| T12 (Week 12) — Excellent | 5 |
| T12 (Week 12) — Missing | 20 |
| VF (Virologic Failure) — Poor | 0 |
| VF (Virologic Failure) — Fair | 0 |
| VF (Virologic Failure) — Good | 3 |
| VF (Virologic Failure) — Very Good | 3 |
| VF (Virologic Failure) — Excellent | 1 |
| VF (Virologic Failure) — Missing | 34 |
Subjects will rate their current state of health via Visual Analog Scale (VAS) using the line as a guide, with 0 as death or worst possible health and 100 as perfect or best possible health. A higher score indicates best outcome. Subjects may experience Virologic Failure (VF) any time during the treatment phase from week 1 to week 14. Subjects who experience VF will be followed up every 4 weeks until the viral load suppression is achieved (i.e., plasma HIV-1 RNA levels to return back to \<50 copies/mL)
| score on a scale | PRO 140 350mg |
|---|---|
| T1 (Week 1) | 82.3 ± 16.4 |
| T4 (Week 4) | 83.8 ± 16.2 |
| T8 (Week 8) | 80.9 ± 18.0 |
| T12 (Week 12) | 84.9 ± 17.3 |
| VF (Viral Failure) | 78.0 ± 15.8 |
Injection site reaction pain assessment @ injection site 1. Each subject received half the total dose of the IP into two separate injection sites. (injection site 1 and injection site 2) at each treatment visit. The information is reported under separate outcomes measures for each injection site.
| Participants | PRO 140 350 mg Weekly SQ Injection |
|---|---|
| T1 (Week 1) — absent | 43 |
| T1 (Week 1) — present | 0 |
| T2 (Week 2) — absent | 43 |
| T2 (Week 2) — present | 0 |
| T3 (Week 3) — absent | 43 |
| T3 (Week 3) — present | 0 |
| T4 (Week 4) — absent | 43 |
| T4 (Week 4) — present | 0 |
| T5 (Week 5) — absent | 43 |
| T5 (Week 5) — present | 0 |
| T6 (Week 6) — absent | 43 |
| T6 (Week 6) — present | 0 |
| T7 (Week 7) — absent | 41 |
| T7 (Week 7) — present | 0 |
| T8 (Week 8) — absent | 36 |
| T8 (Week 8) — present | 0 |
| T9 (Week 9) — absent | 33 |
| T9 (Week 9) — present | 0 |
| T10 (Week 10) — absent | 29 |
| T10 (Week 10) — present | 0 |
| T11 (Week 11) — absent | 29 |
| T11 (Week 11) — present | 0 |
| T12 (Week 12) — absent | 27 |
| T12 (Week 12) — present | 0 |
| T13 (Week 13) — absent | 22 |
| T13 (Week 13) — present | 1 |
| T14 (Week 14) — absent | 6 |
| T14 (Week 14) — present | 0 |
Injection site reaction pain assessment @ injection site 2. Each subject received half the total dose of the IP into two separate injection sites. (injection site 1 and injection site 2) at each treatment visit. The information is reported under separate outcomes measures for each injection site.
| Participants | PRO 140 350mg |
|---|---|
| T1 (Week 1) — absent | 43 |
| T1 (Week 1) — present | 0 |
| T2 (Week 2) — absent | 43 |
| T2 (Week 2) — present | 0 |
| T3 ( Week 3) — absent | 43 |
| T3 ( Week 3) — present | 0 |
| T4 (Week 4) — absent | 43 |
| T4 (Week 4) — present | 0 |
| T5 (Week 5) — absent | 43 |
| T5 (Week 5) — present | 0 |
| T6 (Week 6) — absent | 43 |
| T6 (Week 6) — present | 0 |
| T7 (Week 7) — absent | 41 |
| T7 (Week 7) — present | 0 |
| T8 (Week 8) — absent | 36 |
| T8 (Week 8) — present | 0 |
| T9 (Week 9) — absent | 29 |
| T9 (Week 9) — present | 0 |
| T10 (Week 10) — absent | 29 |
| T10 (Week 10) — present | 0 |
| T11 (Week 11) — absent | 29 |
| T11 (Week 11) — present | 0 |
| T12 (Week 12) — absent | 27 |
| T12 (Week 12) — present | 0 |
| T13 (Week 13) — absent | 23 |
| T13 (Week 13) — present | 0 |
| T14 ( Week 14) — absent | 6 |
| T14 ( Week 14) — present | 0 |
Summary of injection site reaction assessment - Injection site status @ injection site 1. Each subject received half the total dose of the IP into two separate injection sites. (injection site 1 and injection site 2) at each treatment visit. The information is reported under separate outcomes measures for each injection site.
| Participants | PRO 140 350mg |
|---|---|
| T1 (Week 1) — Normal | 43 |
| T1 (Week 1) — abnormal | 0 |
| T2 (Week 2) — Normal | 43 |
| T2 (Week 2) — abnormal | 0 |
| T3 (Week 3) — Normal | 43 |
| T3 (Week 3) — abnormal | 0 |
| T4 (Week 4) — Normal | 43 |
| T4 (Week 4) — abnormal | 0 |
| T5 (Week 5) — Normal | 43 |
| T5 (Week 5) — abnormal | 0 |
| T6 (Week 6) — Normal | 42 |
| T6 (Week 6) — abnormal | 1 |
| T7 (Week 7) — Normal | 41 |
| T7 (Week 7) — abnormal | 0 |
| T8 (Week 8) — Normal | 36 |
| T8 (Week 8) — abnormal | 0 |
| T9 (Week 9) — Normal | 33 |
| T9 (Week 9) — abnormal | 0 |
| T10 (Week 10) — Normal | 29 |
| T10 (Week 10) — abnormal | 0 |
| T11 (Week 11) — Normal | 29 |
| T11 (Week 11) — abnormal | 0 |
| T12 (Week 12) — Normal | 27 |
| T12 (Week 12) — abnormal | 0 |
| T13 (Week 13) — Normal | 23 |
| T13 (Week 13) — abnormal | 0 |
| T14 (Week 14) — Normal | 6 |
| T14 (Week 14) — abnormal | 0 |
Summary of injection site reaction assessment - Injection site status @ injection site 2. Each subject received half the total dose of the IP into two separate injection sites. (injection site 1 and injection site 2) at each treatment visit. The information is reported under separate outcomes measures for each injection site.
| Participants | PRO 140 350 mg Weekly SQ Injection |
|---|---|
| T1 (Week 1) — Normal | 43 |
| T1 (Week 1) — Abnormal | 0 |
| T2 (Week 2) — Normal | 43 |
| T2 (Week 2) — Abnormal | 0 |
| T3 (Week 3) — Normal | 43 |
| T3 (Week 3) — Abnormal | 0 |
| T4 (Week 4) — Normal | 43 |
| T4 (Week 4) — Abnormal | 0 |
| T5 (Week 5) — Normal | 43 |
| T5 (Week 5) — Abnormal | 0 |
| T6 (Week 6) — Normal | 42 |
| T6 (Week 6) — Abnormal | 1 |
| T7 (Week 7) — Normal | 41 |
| T7 (Week 7) — Abnormal | 0 |
| T8 (Week 8) — Normal | 36 |
| T8 (Week 8) — Abnormal | 0 |
| T9 (Week 9) — Normal | 33 |
| T9 (Week 9) — Abnormal | 0 |
| T10 (Week 10) — Normal | 29 |
| T10 (Week 10) — Abnormal | 0 |
| T11 (Week 11) — Normal | 29 |
| T11 (Week 11) — Abnormal | 0 |
| T12 (Week 12) — Normal | 27 |
| T12 (Week 12) — Abnormal | 0 |
| T13 (Week 13) — Normal | 23 |
| T13 (Week 13) — Abnormal | 0 |
| T14 (Week 14) — Normal | 6 |
| T14 (Week 14) — Abnormal | 0 |
Summary of injection site reaction assessment - Pruritus with injection @Site 1. Each subject received half the total dose of the IP into two separate injection sites. (injection site 1 and injection site 2) at each treatment visit. The information is reported under separate outcomes measures for each injection site.
| Participants | PRO 140 350mg |
|---|---|
| T1 (Week 1) — Absent | 43 |
| T1 (Week 1) — Present | 0 |
| T2 (Week 2) — Absent | 42 |
| T2 (Week 2) — Present | 1 |
| T3 (Week 3) — Absent | 43 |
| T3 (Week 3) — Present | 0 |
| T4 (Week 4) — Absent | 43 |
| T4 (Week 4) — Present | 0 |
| T5 (Week 5) — Absent | 43 |
| T5 (Week 5) — Present | 0 |
| T6 (Week 6) — Absent | 43 |
| T6 (Week 6) — Present | 0 |
| T7 (Week 7) — Absent | 41 |
| T7 (Week 7) — Present | 0 |
| T8 (Week 8) — Absent | 36 |
| T8 (Week 8) — Present | 0 |
| T9 (Week 9) — Absent | 33 |
| T9 (Week 9) — Present | 0 |
| T10 (Week 10) — Absent | 29 |
| T10 (Week 10) — Present | 0 |
| T11 (Week 11) — Absent | 29 |
| T11 (Week 11) — Present | 0 |
| T12 (Week 12) — Absent | 27 |
| T12 (Week 12) — Present | 0 |
| T13 (Week 13) — Absent | 23 |
| T13 (Week 13) — Present | 0 |
| T14 (Week 14) — Absent | 6 |
| T14 (Week 14) — Present | 0 |
Summary of injection site reaction assessment - Pruritus with injection @ Site 2. Each subject received half the total dose of the IP into two separate injection sites. (injection site 1 and injection site 2) at each treatment visit. The information is reported under separate outcomes measures for each injection site.
| Participants | PRO 140 350mg |
|---|---|
| T1 (Week 1) — Absent | 43 |
| T1 (Week 1) — Present | 0 |
| T2 (Week 2) — Absent | 42 |
| T2 (Week 2) — Present | 1 |
| T3 (Week 3) — Absent | 43 |
| T3 (Week 3) — Present | 0 |
| T4 (Week 4) — Absent | 43 |
| T4 (Week 4) — Present | 0 |
| T5 (Week 5) — Absent | 43 |
| T5 (Week 5) — Present | 0 |
| T6 (Week 6) — Absent | 43 |
| T6 (Week 6) — Present | 0 |
| T7 (Week 7) — Absent | 41 |
| T7 (Week 7) — Present | 2 |
| T8 (Week 8) — Absent | 36 |
| T8 (Week 8) — Present | 0 |
| T9 (Week 9) — Absent | 33 |
| T9 (Week 9) — Present | 0 |
| T10 (Week 10) — Absent | 29 |
| T10 (Week 10) — Present | 0 |
| T11 (Week 11) — Absent | 29 |
| T11 (Week 11) — Present | 0 |
| T12 (Week 12) — Absent | 27 |
| T12 (Week 12) — Present | 0 |
| T13 (Week 13) — Absent | 23 |
| T13 (Week 13) — Present | 0 |
| T14 (Week 14) — Absent | 6 |
| T14 (Week 14) — Present | 0 |
Summary of injection site reaction assessment - bleeding @ Site 1. Each subject received half the total dose of the IP into two separate injection sites. (injection site 1 and injection site 2) at each treatment visit. The information is reported under separate outcomes measures for each injection site.
| Participants | PRO 140 350mg |
|---|---|
| T1 (Week 1) — Absent | 43 |
| T1 (Week 1) — Present | 0 |
| T2 (Week 2) — Absent | 43 |
| T2 (Week 2) — Present | 0 |
| T3 (Week 3) — Absent | 43 |
| T3 (Week 3) — Present | 0 |
| T4 (Week 4) — Absent | 43 |
| T4 (Week 4) — Present | 0 |
| T5 (Week 5) — Absent | 43 |
| T5 (Week 5) — Present | 0 |
| T6 (Week 6) — Absent | 43 |
| T6 (Week 6) — Present | 0 |
| T7 (Week 7) — Absent | 41 |
| T7 (Week 7) — Present | 0 |
| T8 (Week 8) — Absent | 36 |
| T8 (Week 8) — Present | 0 |
| T9 (Week 9) — Absent | 33 |
| T9 (Week 9) — Present | 0 |
| T10 (Week 10) — Absent | 29 |
| T10 (Week 10) — Present | 0 |
| T11 (Week 11) — Absent | 29 |
| T11 (Week 11) — Present | 0 |
| T12 (Week 12) — Absent | 27 |
| T12 (Week 12) — Present | 0 |
| T13 (Week 13) — Absent | 23 |
| T13 (Week 13) — Present | 0 |
| T14 (Week 14) — Absent | 6 |
| T14 (Week 14) — Present | 0 |
Summary of injection site reaction assessment - bleeding @ Site 2. Each subject received half the total dose of the IP into two separate injection sites. (injection site 1 and injection site 2) at each treatment visit. The information is reported under separate outcomes measures for each injection site.
| Participants | PRO 140 350mg |
|---|---|
| T1 (Week 1) — Absent | 43 |
| T1 (Week 1) — Present | 0 |
| T2 (Week 2) — Absent | 43 |
| T2 (Week 2) — Present | 0 |
| T3 (Week 3) — Absent | 43 |
| T3 (Week 3) — Present | 0 |
| T4 (Week 4) — Absent | 43 |
| T4 (Week 4) — Present | 0 |
| T5 (Week 5) — Absent | 42 |
| T5 (Week 5) — Present | 0 |
| T6 (Week 6) — Absent | 42 |
| T6 (Week 6) — Present | 0 |
| T7 (Week 7) — Absent | 41 |
| T7 (Week 7) — Present | 0 |
| T8 (Week 8) — Absent | 36 |
| T8 (Week 8) — Present | 0 |
| T9 (Week 9) — Absent | 33 |
| T9 (Week 9) — Present | 0 |
| T10 (Week 10) — Absent | 29 |
| T10 (Week 10) — Present | 0 |
| T11 (Week 11) — Absent | 29 |
| T11 (Week 11) — Present | 0 |
| T12 (Week 12) — Absent | 26 |
| T12 (Week 12) — Present | 1 |
| T13 (Week 13) — Absent | 23 |
| T13 (Week 13) — Present | 0 |
| T14 (Week 14) — Absent | 6 |
| T14 (Week 14) — Present | 0 |
Summary of injection site reaction assessment - drug absorption @ Site 1. Each subject received half the total dose of the IP into two separate injection sites. (injection site 1 and injection site 2) at each treatment visit. The information is reported under separate outcomes measures for each injection site.
| Participants | PRO 140 350mg |
|---|---|
| T1 (Week 1) — Normal | 43 |
| T1 (Week 1) — Abnormal | 0 |
| T2 (Week 2) — Normal | 43 |
| T2 (Week 2) — Abnormal | 0 |
| T3 (Week 3) — Normal | 43 |
| T3 (Week 3) — Abnormal | 0 |
| T4 (Week 4) — Normal | 43 |
| T4 (Week 4) — Abnormal | 0 |
| T5 (Week 5) — Normal | 43 |
| T5 (Week 5) — Abnormal | 0 |
| T6 (Week 6) — Normal | 43 |
| T6 (Week 6) — Abnormal | 0 |
| T7 (Week 7) — Normal | 41 |
| T7 (Week 7) — Abnormal | 0 |
| T8 (Week 8) — Normal | 36 |
| T8 (Week 8) — Abnormal | 0 |
| T9 (Week 9) — Normal | 33 |
| T9 (Week 9) — Abnormal | 0 |
| T10 (Week 10) — Normal | 29 |
| T10 (Week 10) — Abnormal | 0 |
| T11 (Week 11) — Normal | 29 |
| T11 (Week 11) — Abnormal | 0 |
| T12 (Week 12) — Normal | 27 |
| T12 (Week 12) — Abnormal | 0 |
| T13 (Week 13) — Normal | 23 |
| T13 (Week 13) — Abnormal | 0 |
| T14 (Week 14) — Normal | 6 |
| T14 (Week 14) — Abnormal | 0 |
Summary of injection site reaction assessment - drug absorption @ Site 2. Each subject received half the total dose of the IP into two separate injection sites. (injection site 1 and injection site 2) at each treatment visit. The information is reported under separate outcomes measures for each injection site.
| Participants | PRO 140 350mg |
|---|---|
| T1 (Week 1) — Normal | 43 |
| T1 (Week 1) — Abnormal | 0 |
| T2 (Week 2) — Normal | 43 |
| T2 (Week 2) — Abnormal | 0 |
| T3 (Week 3) — Normal | 43 |
| T3 (Week 3) — Abnormal | 0 |
| T4 (Week 4) — Normal | 43 |
| T4 (Week 4) — Abnormal | 0 |
| T5 (Week 5) — Normal | 43 |
| T5 (Week 5) — Abnormal | 0 |
| T6 (Week 6) — Normal | 43 |
| T6 (Week 6) — Abnormal | 0 |
| T7 (Week 7) — Normal | 41 |
| T7 (Week 7) — Abnormal | 0 |
| T8 (Week 8) — Normal | 36 |
| T8 (Week 8) — Abnormal | 0 |
| T9 (Week 9) — Normal | 33 |
| T9 (Week 9) — Abnormal | 0 |
| T10 (Week 10) — Normal | 29 |
| T10 (Week 10) — Abnormal | 0 |
| T11 (Week 11) — Normal | 29 |
| T11 (Week 11) — Abnormal | 0 |
| T12 (Week 12) — Normal | 27 |
| T12 (Week 12) — Abnormal | 0 |
| T13 (Week 13) — Normal | 23 |
| T13 (Week 13) — Abnormal | 0 |
| T14 (Week 14) — Normal | 6 |
| T14 (Week 14) — Abnormal | 0 |
Summary of injection site pain assessment (VAS) post injection mean change from baseline. Subject-perceived injection site pain was assessed using the Pain Visual Analog Scale (VAS) post study treatment administration assessing average pain. Higher score is worse outcome. Each subject received half the total dose of the IP into two separate injection sites. (injection site 1 and injection site 2) at each treatment visit. The information is reported under separate outcomes measures for each injection site.
| score on a scale | PRO 140 350mg |
|---|---|
| T1 (Week 1) | 18.4 ± 16.1 |
| T2 (Week 2) | -3.9 ± 8.6 |
| T3 (Week 3) | -7.9 ± 11.4 |
| T4 (Week 4) | -2.5 ± 14.2 |
| T5 (Week 5) | -12.8 ± 13.9 |
| T6 (Week 6) | -6.8 ± 16.7 |
| T7 (Week 7) | -13.5 ± 13.9 |
| T8 (Week 8) | -16.6 ± 14.8 |
| T9 (Week 9) | -15.0 ± 14.2 |
| T10 (Week 10) | -17.2 ± 12.3 |
| T11 (Week 11) | -24.0 ± 18.1 |
| T12 (Week 12) | -22.0 ± 18.4 |
| T13 (Week 13) | -17.0 ± 15.6 |
| T14 (Week 14) | -22.0 ± 19.1 |
Summary of injection site pain assessment (VAS) post injection @ Site 2. Subject-perceived injection site pain was assessed using the Pain Visual Analog Scale (VAS) post study treatment administration assessing average pain. A higher score is a worse outcome. Each subject received half the total dose of the IP into two separate injection sites. (injection site 1 and injection site 2) at each treatment visit. The information is reported under separate outcomes measures for each injection site.
| score on a scale | PRO 140 350mg |
|---|---|
| T1 (Week 1) | 17.4 ± 15.2 |
| T2 (Week 2) | -2.0 ± 14.2 |
| T3 (Week 3) | -4.8 ± 11.8 |
| T4 (Week 4) | -7.8 ± 12.2 |
| T5 (Week 5) | -8.8 ± 15.7 |
| T6 (Week 6) | -7.2 ± 17.6 |
| T7 (Week 7) | -10.4 ± 14.8 |
| T8 (Week 8) | -13.0 ± 15.9 |
| T9 (Week 9) | -14.6 ± 16.0 |
| T10 (Week 10) | -10.7 ± 9.1 |
| T11 (Week 11) | -14.7 ± 13.3 |
| T12 (Week 12) | -15.2 ± 14.8 |
| T13 (Week 13) | -10.0 ± 10.3 |
| T14 (Week 14) | -13.8 ± 18.5 |
Summary of injection site pain assessment (VAS) pre injection @ Site 1 Subject-perceived injection site pain was assessed using the Pain Visual Analog Scale (VAS) prior to study treatment administration assessing average pain since last treatment. Higher score is a worse outcome. Each subject received half the total dose of the IP into two separate injection sites. (injection site 1 and injection site 2) at each treatment visit. The information is reported under separate outcomes measures for each injection site.
| score on a scale | PRO 140 350mg |
|---|---|
| T2 (Week 2) | 0.0 ± 0.0 |
| T3 (Week 3) | 2.8 ± 8.4 |
| T4 (Week 4) | 1.7 ± 6.6 |
| T5 (Week 5) | 2.2 ± 4.2 |
| T6 (Week 6) | 1.6 ± 4.2 |
| T7 (Week 7) | 1.0 ± 4.0 |
| T8 (Week 8) | 0.9 ± 3.6 |
| T9 (Week 9) | 1.6 ± 4.1 |
| T10 (Week 10) | 1.5 ± 5.9 |
| T11 (Week 11) | 1.3 ± 4.7 |
| T12 (Week 12) | 0.5 ± 4.1 |
| T13 (Week 13) | 0.6 ± 1.3 |
| T14 (Week 14) | 0.0 ± NA |
Summary of injection site pain assessment (VAS) pre injection @ Site 2. Subject-perceived injection site pain was assessed using the Pain Visual Analog Scale (VAS) prior to study treatment administration assessing average pain since last treatment. Higher score is a worse outcome. Each subject received half the total dose of the IP into two separate injection sites. (injection site 1 and injection site 2) at each treatment visit. The information is reported under separate outcomes measures for each injection site.
| score on a scale | PRO 140 350mg |
|---|---|
| T2 (Week 2) | 0.0 ± 0.0 |
| T3 (Week 3) | 2.4 ± 9.2 |
| T4 (Week 4) | 4.8 ± 19.9 |
| T5 (Week 5) | 2.1 ± 7.1 |
| T6 (Week 6) | 2.0 ± 7.1 |
| T7 (Week 7) | 0.8 ± 6.9 |
| T8 (Week 8) | 1.1 ± 6.5 |
| T9 (Week 9) | 1.9 ± 7.2 |
| T10 (Week 10) | 1.7 ± 8.5 |
| T11 (Week 11) | 1.4 ± 7.7 |
| T12 (Week 12) | 0.1 ± 5.3 |
| T13 (Week 13) | 0.4 ± 0.8 |
| T14 (Week 14) | 0.0 ± NA |
Summary of Pro 140 Concentration. Subjects may experience Virologic Failure (VF) any time during the treatment phase from week 1 to week 14. Subjects who experience VF will be followed up every 4 weeks until the viral load suppression is achieved (i.e., plasma HIV-1 RNA levels to return back to \<50 copies/mL).
| ng/ml | PRO 140 350mg |
|---|---|
| T4 (Week 4) | 18084 (8152 to 37318) |
| T8 (Week 8) | 22010 (6965 to 41624) |
| T12 (Week 12) | 26388 (11632 to 74414) |
| VF (Viral Failure) | 16258 (8133 to 26396) |
Collected over Adverse events were collected for a total of 18 weeks, from treatment visit 1 (Post Rx) to treatment visit T14 (Week 14) and through the follow up period, every 2 week for total of 4 weeks. The duration of follow-up depends on the status of viral load suppression. Subjects who experience Virologic Failure will be discontinued from the treatment phase and be followed up every 4 weeks until the viral load suppression is achieved (i.e., plasma HIV-1 RNA levels to return back to <50 copies/mL).. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Leronlimab | 0/43 (0%) | 1/43 (2.3%) | 7/43 (16.3%) |
| Event | Leronlimab |
|---|---|
| transient ischemic attackNervous system disorders | 1/43 |
| Event | Leronlimab |
|---|---|
| nasopharyngitisInfections and infestations | 4/43 |
| DiarrhoeaGastrointestinal disorders | 4/43 |
| nauseaGastrointestinal disorders | 4/43 |
| FatigueGeneral disorders | 4/43 |
| Injection site pruritusGeneral disorders | 4/43 |
| ConstipationGastrointestinal disorders | 3/43 |
| DizzinessNervous system disorders | 3/43 |
| Age, Continuous(years) | PRO 140 |
|---|---|
| Mean | 53.1 ± 10 |
| Sex: Female, Male(Participants) | PRO 140 |
|---|---|
| Female | 3 |
| Male | 40 |
| Ethnicity (NIH/OMB)(Participants) | PRO 140 |
|---|---|
| Hispanic or Latino | 9 |
| Not Hispanic or Latino | 34 |
| Unknown or Not Reported | 0 |
| Race (NIH/OMB)(Participants) | PRO 140 |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 0 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 4 |
| White | 34 |
| More than one race | 0 |
| Unknown or Not Reported | 5 |
| Time since HIV Diagnosis (Years)(years) | PRO 140 |
|---|---|
| Mean | 18.8 ± 9.5 |
Plan to share: No
Ran from Apr 2014 to primary completion in Feb 2015, 9 months.
Results were first posted in Apr 2023, 8 years 2 months after primary completion.
Of 29 industry-sponsored phase 2 interventional studies under Acquired Immunodeficiency Syndrome, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 71. This study's 9 months is below that.
Counting every sponsor, half of 86 studies reached it within 36 months; a quarter within 18 and three quarters within 71.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Leronlimab
Acquired Immunodeficiency Syndrome →